

Case 1646 #9

COPY OF PAPERS  
ORIGINALLY FILED



Attorney Docket No.: 6296.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Van Den Berghe, Greta

RECEIVED

Serial No.: 09/853,193

Group Art Unit: 1646

MAR 19 2002

Filed: May 11, 2001

Examiner: To be assigned

TECH CENTER 1600/2900

Confirmation No: 5893

For: Methods and Preparations For Curing Clinically Ill Patients

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of Reference (English Translation)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on March 4, 2002.

Sylvia Gonzalez

(name of person mailing paper)

(signature of person mailing paper)



Attorney Docket No.: 6296.204-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Van Den Berghe, Greta

RECEIVED

Application No.: 09/853,193

Group Art Unit: 1646

MAR 19 2002

Filed: May 11, 2001

Examiner: To be assigned

TECH CENTER 1600/2900

For: Method and Preparations For Curing Clinically Ill Patients

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith an English translation of the reference listed below. The French language version of this reference was previously cited in the Information Disclosure Statement filed on January 23, 2002, in this application. This reference may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the reference may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the reference is "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The reference is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. The reference is as follows:

1. English translation of "Iapichino et al "L'usage de l'insulin comme agent anabolisant doit-il être préconisé chez le sujet dénutri ou agressé" Nutr. Clin. Metabol. Vol. 10, pgs. 243-252

It is respectfully requested that this reference be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

It is believed that no fee is due for submission and entry of this Supplemental Information Disclosure Statement as it is prior to the first Office Action on the merits and provides an English language translation of a reference previously submitted in the Information Disclosure Statement submitted on January 23, 2002 in this application.

It is determined that a fee is due for entry and consideration of the Supplemental Information Statement, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 14-1447.

Respectfully submitted,

Date: March 4, 2002

Richard W. Bork  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650  
PATENT TRADEMARK OFFICE